GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan.
Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability
The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic
Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options